Wall Street Ends Higher as S&P 500, Nasdaq Extend Gains Ahead of Holiday Week 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Yen Stabilizes Near Lows as Japan Signals Readiness to Intervene Amid Dollar Weakness 
Taiwan Stock Market Ends Higher as Semiconductor and Energy Shares Lead Gains 
UBS Warns of Short-Term Risks as Precious Metals Rally to Record Highs 
Oil Prices Edge Higher as Strong U.S. Growth and Supply Risks Support Market 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
U.S. Stocks Rally to Record Highs as AI Rebound Fuels Holiday-Shortened Session 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Asian Stocks and Gold Rally as Investors Chase Year-End Gains Amid Dollar Weakness 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
IMF Reaches Staff-Level Agreement With Egypt, Opening Path to $3.8 Billion in Funding 
BOJ Minutes Reveal Growing Debate Over Interest Rate Hikes and Inflation Risks 
Oil Prices Ease in Asia as Geopolitical Risks Clash With Weak Demand Outlook 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Japan Plans $189 Billion Bond Issuance as Record Budget Signals Expansionary Fiscal Policy 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Samsung Biologics and Biogen, an American biotechnology company, based in Cambridge, Massachusetts, signed a deal for the transfer of stake in Samsung Boiepis. The South Korean biotech firm headquartered in Songdo, Incheon, is buying all of Biogen’s stake in the biopharma company.
Samsung Bioepis was formed in 2012 via a joint venture between Samsung Biologics and Biogen. The latter owned a 15% stake at first, and in 2018, the percentage was increased to 50% as it extended its controlling rights in the company.
As per The Korea Herald, the acquisition of Biogen’s stake is predicted to help boost Samsung Biologic’s competitiveness in the global bio market. The value of the deal is ₩2.7 trillion or around $2.3 billion.
The total shares acquired are 10,341,852 units, and Samsung Biologics stated that the company’s board of directors approved the transaction. The payments for the stakes are set to be made in installments and will be paid over the next two years.
The full ownership of the shares will take effect once the first payment of $1 billion is completed. It was revealed that it was Biogen that forwarded a request for the buyout deal. Despite the acquisition, both companies said they would continue to work as close partners.
“We are thankful to Samsung Biologics for a productive collaboration since 2012,” Biogen’s chief executive officer, Michel Vounatsos, said in a press release. “We believe biosimilars are essential to help sustain healthcare systems and represent an important value creation opportunity for Biogen.”
With the transaction, Samsung Biologics Co. will take over and be in full control of Samsung Bioepis Co. since the deal is for the entire holdings of Biogen’s shares. Pulse News reported that the transfer of shares is set to take place on April 30, 2022.
Meanwhile, Samsung Bioepis is currently developing five biosimilar drugs that it will be launching worldwide. One of them is just waiting for approval and ready for marketing. The four other drugs are in the third phase of clinical trials. Two of the medicines are for oncology, and three are formulated for autoimmune.
